CRP and amyotrophic lateral sclerosis: Targeting IL-6 signaling has proposed as a therapeutic strategy in ALS: in a clinical trial, IL-6 receptor blocker tocilizumab (Actemra) was reported to decrease C-reactive protein (CRP) levels in plasma and CSF, in addition to being well tolerated and safe in ALS patients (Milligan et al., 2021).